Cardiovascular risk factors such as hypertension, hyperlipidemia and glucose intolerance are highly prevalent in Cushing’s syndrome. Lipid abnormalities have been reported in 40–70% of patients, including those with ‘subclinical’ disease. Surgical cure is associated with significant amelioration of lipid profile in the majority of patients. Treatment of persistent hyperlipidemia should be conducted according to the accepted general principles in use for other medical conditions. Nevertheless, patients requiring medical treatment for persistent hypercortisolism present specific challenges, according to the selected therapeutic agent. For example, treatment with the adrenolytic drug o,p’DDD is associated with a prominent increase in cholesterol levels that necessitates intensive use of lipid lowering agents. The use of ketoconazole, a potent inhibitor of cytochrome P450 3A4 (CYP3A4), may significantly increase plasma concentrations of certain statins (such as simvastatin and atorvastatin) that undergo metabolism by the same pathway, thus increasing the risk of complications and side effects. Therefore, preference should be given to HMG-CoA inhibitors that are metabolized by different pathways, such as pravastatin. In summary, hyperlipidemia should be aggressively treated in patients with Cushing’s syndrome in view of the increased cardiovascular morbidity and mortality associated with this disorder.

Keywords:
Hyperlipidemia, Ketoconazole
1.
Plotz CM, Knowlton AI, Ragan C: The natural history of Cushing’s syndrome. Am J Med 1952;13:597–614.
2.
Etxabe J, Vasquez JA: Morbidity and mortality in Cushing’s disease: and epidemiological approach. Clin Endocrinol 1994;40:479–484.
3.
Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M: Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 2003;88:5593–5602.
4.
Wei L, MacDonald TM, Walker BR: Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004;141:764–770.
5.
Tauchmanovà L, Rossi R, Biondi B, Pulcrano M, Nuzzo V, Palmieri EA, Fazio S, Lombardi G: Patients with subclinical Cushing’s syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab 2002;87:4872–4878.
6.
Dekker MJ, Koper JW, van Aken MO, Pols HA, Hofman A, de Jong FH, Kirschbaum C, Witteman JC, Lamberts SW, Tiemeier H: Salivary cortisol is related to atherosclerosis of carotid arteries. J Clin Endocrinol Metab 2008;93:3741–3747.
7.
Samra JS, Clark ML, Humphreys SM, MacDonald IA, Bannister PA, Frayn KN: Effects of physiological hypercortisolemia on the regulation of lipolysis in subcutaneous adipose tissue. J Clin Endocrinol Metab 1998;83:626–631.
8.
van Raalte DH, Ouwens DM, Diamant M: Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest 2009;39:81–93.
9.
Kola B, Christ-Crain M, Lolli F, Arnaldi G, Giacchetti G, Boscaro M, Grossman AB, Korbonits M: Changes in adenosine 5′-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing’s syndrome. J Clin Endocrinol Metab 2008;93:4969–4973.
10.
Taskinen MR, Nikkilä EA, Pelkonen R, Sane T: Plasma lipoproteins, lipolytic enzymes, and very low density lipoprotein triglyceride turnover in Cushing’s syndrome. J Clin Endocrinol Metab 1983;57:619–626.
11.
Fardet L, Cabane J, Kettaneh A, Lebbé C, Flahault A: Corticosteroid-induced lipodystrophy is associated with features of the metabolic syndrome. Rheumatology 2007;46:1102–1106.
12.
Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, Filippella M, Marzullo P, Cerbone G, Siciliani M, Lombardi G: Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure. J Clin Endocrinol Metab 1999;84:2664–2672.
13.
Faggiano A, Pivonello R, Spiezia S, De Martino MC, Filippella M, Di Somma C, Lombardi G, Colao A: Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing’s disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 2003;88:2527–2533.
14.
Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G: High cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol 2004;61:768–777.
15.
Terzolo M, Allasino B, Bosio S, Brusa E, Daffara F, Ventura M, Aroasio E, Sacchetto G, Reimondo G, Angeli A, Camaschella C: Hyperhomocysteinemia in patients with Cushing’s syndrome. J Clin Endocrinol Metab 2004;89:3745–3751.
16.
Erbil Y, Ademoğlu E, Ozbey N, Barbaros U, Yanik BT, Salmaslioğlu A, Bozbora A, Ozarmağan S: Evaluation of the cardiovascular risk in patients with subclinical Cushing syndrome before and after surgery. World J Surg 2006;30:1665–1671.
17.
Toniato A, Merante-Boschin I, Opocher G, Pelizzo MR, Schiavi F, Ballotta E: Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study. Ann Surg 2009;249:388–391.
18.
Danilowicz K, Bruno OD, Manavela M, Gomez RM, Barkan A: Correction of cortisol overreplacement ameliorates morbidities in patients with hypopituitarism: a pilot study. Pituitary 2008;11:279–285.
19.
Igaz P, Tömböl Z, Szabó PM, Likó I, Rácz K: Steroid biosynthesis inhibitors in the therapy of hypercortisolism: theory and practice. Curr Med Chem 2008;15:2734–2747.
20.
Gylling H, Vanhanen H, Miettinen TA: Effects of ketoconazole on cholesterol precursors and low density lipoprotein kinetics in hypercholesterolemia. J Lipid Res 1993;34:59–67.
21.
Gylling H, Vanhanen H, Miettinen TA: Hypolipidemic effect and mechanism of ketoconazole without and with cholestyramine in familial hypercholesterolemia. Metabolism 1991;40:35–41.
22.
Terzolo M, Pia A, Berruti A, Osella G, Alì A, Carbone V, Testa E, Dogliotti L, Angeli A: Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. J Clin Endocrinol Metab 2000;85:2234–2238.
23.
Kawai S, Ichikawa Y, Kaburaki J, Yoshida T: 18 years mitotane therapy for intractable Cushing’s disease. Lancet 1999;354:951.
24.
Maher VM, Trainer PJ, Scoppola A, Anderson JV, Thompson GR, Besser GM: Possible mechanism and treatment of o,p’DDD-induced hypercholesterolaemia. Q J Med 1992;84:671–679.
25.
Neuvonen PJ, Niemi M, Backman JT: Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80:565–581.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.